Status:
COMPLETED
Serum Endostatin Type 2 Diabetic Patients
Lead Sponsor:
Zagazig University
Conditions:
Diabetes Mellitus, Type 2
Coronary Artery Disease
Eligibility:
All Genders
50-70 years
Brief Summary
To assess the relationship between serum endostatin (ES) and Coronary artery calcification (CAC) in type 2 diabetic (T2DM) patients.
Detailed Description
elevated serum endostatin levels were independently associated with increased risk, severity and progression of coronary artery calcification independent of traditional cardiovascular disease risk fac...
Eligibility Criteria
Inclusion
- Patients were between the ages of 50 and 70 years at enrollment.
- Symptomatic or previously recognized coronary artery disease for all the study population.
- Type 2 diabetic patients with the onset of type 2 diabetes occurred at age 30 years or older with no history of ketoacidosis for group II subjects.
Exclusion
- left ventricular ejection fraction (LVEF) ≤40%, chronic heart failure, unstable angina, Myocardial infarction, arrhythmia, valvular heart disease, coronary artery bypass surgery, and history of stent placement, liver diseases, malignancy, glomerular filtration rate index \< 35 mL/min/m2, serum creatinine level above 4.5 mg/dL, body mass index \>30 kg/m2 or \< 15 kg/m2, pulmonary edema, stroke, acute infections, severe trauma, recent surgery, inflammatory conditions, thyrotoxicosis, pregnancy and known allergic reactions.
Key Trial Info
Start Date :
March 2 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 20 2017
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT03404037
Start Date
March 2 2017
End Date
December 20 2017
Last Update
January 19 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zagazig University, Faculty of Medicine
Zagazig, Egypt, 44519